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Abstract
There has been a rapid advance in germline multigene panel testing by next-generation sequencing, and it is being widely 
used in clinical settings. A 56-year-old woman suspected of having Lynch syndrome was identified as a BRCA2 pathogenic 
variant carrier by multigene panel testing. The patient was diagnosed with endometrial cancer at the age of 39 years, and 
total laparoscopic hysterectomy and bilateral salpingectomy were performed at the age of 49 years; however, bilateral 
oophorectomy was not performed at that time. As she had a family history of colorectal cancer and a history of endometrial 
cancer, Lynch syndrome was suspected. However, germline multigene panel testing revealed a pathogenic BRCA2 variant 
rather than pathogenic variants in mismatch repair genes. In this case, with conventional genetic risk assessment, we were 
unable to determine whether the patient had a high risk of hereditary breast and ovarian cancer; thus, germline multigene 
panel testing may provide valuable information to improve disease management strategies for patients in clinical settings. 
Particularly, germline multigene panel testing may be useful for detecting hereditary tumor syndromes if a patient does not 
present with a typical family history of cancer.
Keywords BRCA2 · Hereditary breast and ovarian cancer · Multigene panel testing · Genetic counseling · Lynch syndrome
Introduction
During recent years, there has been a rapid advance in 
genetic testing techniques such as next-generation sequenc-
ing, and they are being increasingly used in clinical practice, 
rather than conventional single-gene analysis [1]. Multigene 
panel testing by next-generation sequencing enables simul-
taneous analysis of multiple genes of interest at a lower 
cost than conventional techniques [2–5]. In some cases, 
this tool has provided valuable information that has enabled 
to change clinical management strategies for patients [6]. 
Here, we present a case of an individual suspected of having 
Lynch syndrome, but multigene panel testing revealed that 
the patient was a carrier of a BRCA2 pathogenic variant.
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Case report
Clinical history
The patient, who had no particular history, was diagnosed 
with stage Ia endometrial cancer (FIGO 1988) when she 
was 39 years old. Her height was 158 cm and weight was 
56 kg; the body mass index (BMI) was 22.4. The histologi-
cal subtype was endometrioid carcinoma Grade 1. As the 
patient was never pregnant and hoped to preserve her fertil-
ity, medroxyprogesterone acetate therapy was carried out, 
instead of hysterectomy. As her tumor recurred when she 
was 49 years old, as revealed by the cytological analysis 
(Fig. 1), total laparoscopic hysterectomy and bilateral sal-
pingectomy were performed, but the bilateral ovaries were 
not resected according to her wish. The final histopathologi-
cal diagnosis was endometrioid carcinoma Grade 1 with no 
myometrial invasion (Fig. 2). Figure 3 shows the patient’s 
family tree. On the maternal side, six of her uncles and aunts 
(II-3, 4, 5, 6, 7, and 10), as well as her grandfather (I-3), had 
a history of colorectal cancer. In addition, one of her mater-
nal cousins (III-8) had ovarian cancer and a paternal cousin 
(III-1) had prostate cancer.
Genetic counseling
The attending physician suggested hereditary involvement, 
and genetic counseling was provided based on informed con-
sent when she was 56 years old. First, she was suspected of 
having Lynch syndrome because of her history of endome-
trial cancer and family history of colorectal cancer. How-
ever, we suspected Lynch syndrome, as she fulfilled neither 
the Amsterdam criteria II nor revised Bethesda guidelines; 
moreover, she was not affected by colorectal cancer, and her 
first-degree relatives (specifically, her mother) had no his-
tory of related tumors. Thus, this patient did not show typi-
cal features of Lynch syndrome, although a genetic factor 
was assumed to be functional in the background. Therefore, 
germline panel testing using OncoGuide NCC Oncopanel 
System FC v. 1.0 (Table 1) (Agilent, Tokyo, Japan) was per-
formed in addition to microsatellite instability testing and 
mismatch repair protein immunohistochemistry of endome-
trial specimens.
Results
The stability of microsatellites and the expression of mis-
match repair proteins were not decreased, according to 
microsatellite instability testing and immunohistochem-
istry analysis, respectively (Fig. 4). Germline multigene 
panel testing revealed a BRCA2 pathogenic variant (exon13: 
c.C6952T, p.R2318X).
Clinical management
The patient had a BRCA2 pathogenic variant, and informa-
tion regarding the future risk of breast, ovarian, and pan-
creatic cancers was collected. The option of prophylactic 
resection of either the mammaries (by risk-reducing mas-
tectomy) or ovaries was recommended according to man-
agement guidelines, such as those from the National Com-
prehensive Cancer Network. Genetic counseling for other 
family members considered to be at risk was also consid-
ered. This patient is currently 56 years old, and to date, she 
has not undergone prophylactic surgery. Instead, she is under 
Fig. 1  Cytology of the endometrium. Cell clusters exfoliated from the 
endometrium showed considerable nuclear overlapping. The nuclei 
were irregular and hyperchromatic and had coarse chromatin. Based 
on these findings, endometrioid adenocarcinoma was suspected
Fig. 2  Microscopic analysis of the endometrial specimen stained with 
Hematoxylin and Eosin. The endometrial glands showed a small non-
villous papillary architecture and were lined by cuboidal or columnar 
cells with pale eosinophilic cytoplasm. The nuclei were round and 
enlarged, without appreciable atypia
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surveillance for breast, ovarian, and pancreatic cancers in 
our hospital.
Discussion
In this study, a BRCA2 pathogenic variant was detected 
in the patient. The BRCA2 exon 13 variant c.C6952T, 
p.R2318X was identified as a pathogenic variant accord-
ing to previous studies [7–9]. The frequency of this variant 
has been reported to be 0.44% in Japanese patients with 
breast cancer [8], and this variant has also been reported 
in Japanese patients with ovarian cancer [9]. Here, when 
reviewing the family tree (Fig. 3) with this genetic infor-
mation, it was apparent that one maternal cousin (III-8) 
had a history of ovarian cancer, one paternal cousin (III-1) 
had prostate cancer, and no family member on either side 
had breast cancer. As prostate cancer is also related to 
hereditary breast and ovarian cancer (HBOC), it is difficult 
to determine the family member from whom the BRCA2 
variant was derived. Additional examination in other 
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Fig. 3  Family tree. The patient in this case is indicated with an arrow. 
The black squares and circles indicate family members with a history 
of malignancy. d., age at death; dx., age at diagnosis. II-3, -7, -11, 
and -12 have two children each, and II-4, -5, and -6 have three chil-
dren each, none of them were affected by any related tumors (data not 
shown)
Table 1  List of 121 genes analyzed using the NCC oncopanel system FC v. 1.0
AIP BRCA1 CYLD FANCA GALNT12 MITF PALLD PTCH2 SDHA TGFBR2 XRCC2
AKT1 BRCA2 DDB2 FANCB GEN1 MLH1 PHOX2B PTEN SDHAF2 TMEM127
ALK BRIP1 DICER1 FANCC GOLGA5 MLH3 PIK3CA RAD50 SDHB TP53
APC CDC73 EGFR FANCD2 GREM1 MRE11A PMS2 RAD51B SDHC TP53BP1
ATM CDH1 EGLN1 FANCE HOXB13 MSH2 POLD1 RAD51C SDHD TSC1
ATR CDK4 ELAC2 FANCF KIF1B MSH3 POLE RAD51D SLX4 TSC2
AXIN1 CDKN1B EPCAM FANCG KIT MSH6 POLH RB1 SMAD4 TSHR
AXIN2 CDKN2A ERBB2 FANCI KRAS MUTYH PPM1D RBM15 SMARCB1 VHL
BAP1 CHEK1 ESR1 FANCL MAX NBN PRKAR1A RECQL4 SMARCE1 WRN
BARD1 CHEK2 EXT1 FANCM MC1R NF1 PRKDC RET STK11 WT1
BLM CTNNA1 EXT2 FH MEN1 NF2 PRSS1 RHBDF2 SUFU XPA
BMPR1A CTNNB1 FAM175A FLCN MET PALB2 PTCH1 RNF139 TERT XPC
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family members should be considered to clarify heredi-
tary tumor involvement and perform segregation analysis.
One of the most important clinical considerations in this 
case was that the bilateral ovaries of the patient were not 
resected. In addition, the fallopian tubes were not patho-
logically examined in accordance with the SEE-FIM proto-
col at that time. When total laparoscopic hysterectomy and 
bilateral salpingectomy were performed to treat her endome-
trial cancer, there was no information regarding her BRCA2 
pathogenic variant. On the contrary, this patient did not meet 
the BRCA1/2 testing criteria of the National Comprehensive 
Cancer Network Guidelines (v. 3, 2019), as she had no his-
tory of breast or ovarian cancer and only one of her cousins 
had ovarian cancer. Therefore, it was difficult to evaluate 
the risk of HBOC in this patient using only the personal and 
family histories. In contrast, if multigene panel testing had 
been performed before surgery, this patient could have opted 
bilateral salpingo-oophorectomy based on the future ovarian 
cancer risk; moreover, the fallopian tubes should have been 
appropriately examined.
Thus, multigene panel testing may change disease man-
agement in clinical settings based on results that cannot 
be obtained from either conventional risk assessments or 
single-gene analysis. Indeed, previous studies have indicated 
that multigene panel testing can increase the detection rate 
of any pathogenic variant (including non-BRCA 1/2 variants, 
such as Lynch syndrome genes) in patients suspected with 
HBOC, and this can alter clinical management strategies for 
cancers [6, 10]. Kurian et al. also reported that BRCA1/2-
only testing is being replaced by multiple-gene sequencing 
for patients with breast cancer [11]. Furthermore, some 
previous studies identified BRCA2 pathogenic variants in 
patients with colorectal cancer based on the age at diagno-
sis or family history of colorectal cancers [12, 13]. Here, 
we suggest that multigene panel testing is also useful for 
improving the clinical management strategies of patients 
who had been primarily suspected to have Lynch syndrome 
and not HBOC.
However, several issues should be considered when per-
forming multigene panel testing. For example, there may be 
some differences in the targeted genes or variant annotations 
among the commercially available tests. The possibility of 
identifying variants of unknown significance or variants in 
genes that are not thought to be clinically actionable should 
also be considered. Therefore, single gene analysis could be 
considered for some hereditary tumors, which have char-
acteristic phenotypes, such as, Peutz–Jeghers syndrome. 
Individuals providing genetic counseling should be familiar 
with updated information regarding the problems mentioned 
above.
Regarding the relationship between the BRCA1/2 vari-
ant and endometrial cancer, Shu et al. reported that the risk 
of serous/serous-like endometrial carcinoma increased in 
BRCA1 variant-positive women [14]. In our case, the patient 
had a BRCA2 pathogenic variant, and the endometrial can-
cer histology was endometrioid carcinoma. Therefore, it is 
Fig. 4  Immunohistochemical 
staining of mismatch repair 
proteins. The tumor cell nuclear 
expression of MLH1, MSH6, 
MSH2, and PMS2 was similar 
to that in the surrounding stro-
mal cells
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unclear whether the BRCA2 variant affected the etiology of 
endometrial cancer. On the contrary, this patient did not have 
typical clinical features of endometrial cancer such as obe-
sity or a history of diabetes mellitus. Although nulliparity 
could be a risk factor, it is obscure how the patient developed 
endometrial cancer in her thirties.
In conclusion, we present a case in which multigene panel 
testing revealed a BRCA2 pathogenic variant in a patient who 
had been suspected to have Lynch syndrome, rather than 
HBOC. Clinicians should take detailed history of patients 
and their families, particularly when planning a surgery and 
should carefully choose an appropriate genetic testing tool 
that may confirm or alter the clinical management strategy.
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